Skip to main content
Contact Us
Subscribe
E-Edition
95°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytodyn Inc
(OP:
CYDY
)
0.1260
-0.0038 (-2.93%)
Streaming Delayed Price
Updated: 3:56 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytodyn Inc
< Previous
1
2
3
Next >
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
August 23, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
August 12, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Settlement with Amarex Clinical Research LLC
July 09, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
June 27, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
May 2024 Letter to Shareholders
May 16, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
January 29, 2024
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
November 2023 Letter to Shareholders
November 03, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Company Updates and Investment Community Update Webcast
July 11, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces President Takes Medical Leave of Absence
May 24, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CytoDyn Announces Appointment of Additional Directors with Industry Experience
October 20, 2022
From
CytoDyn Inc.
Via
GlobeNewswire
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 11, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
August 10, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
March 18, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From
CytoDyn Inc.
Via
Business Wire
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
January 10, 2022
From
CytoDyn Inc.
Via
Business Wire
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
January 05, 2022
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
December 22, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
December 21, 2021
From
CytoDyn Inc.
Via
Business Wire
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
December 13, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.